COVID-19 experts were expecting the first vaccines to only be 60% or 70% effective but phase III Pfizer and Biontech results show 90% effectiveness.
Test subjects who received two injections of the vaccine three weeks apart had 90% fewer cases of symptomatic Covid-19 than those who received a placebo.
Pfizer and Biontech will file for emergency use authorization to distribute the vaccine when half of the patients in their study have been observed for any safety issues for at least two months following their second dose.
There still needs to be studies and reports on effectiveness in preventing deaths from COVID-19 and effectiveness in reducing the spread in people who do not show symptoms.
Pfizer says up to 50 million doses could be available globally. by the end of 2021. There will be 1.3 billion doses available in 2021. The vaccine must be stored at super-cold temperatures, which could make it extremely difficult to deliver to many places. Pfizer has said it is confident those issues can be managed.
The number of people who can be vaccinated is half the number of doses because it will take two injections to reach immunity. There have been no studies on how long immunity will last.
SOURCES- Pfizer, Statnews
Written By Brian Wang, Nextbi